Sienna Biopharmaceuticals Inc (SNNA):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Sienna Biopharmaceuticals Inc (SNNA) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7893
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a clinical-stage biopharmaceutical company that develops and commercializes topical products in medical dermatology and aesthetics. Through its topical photoparticle therapy platform, the company advanced its product SNA-001, into pivotal clinical trials for both acne vulgaris and the reduction of unwanted light-pigmented hair. SNA-120, the company’s lead candidate from topical by design platform (TBD), currently in Phase 2b clinical development, is an inhibitor of tropomyosin receptor kinase A intended for the treatment of pruritus and psoriasis. Its second TBD product candidate, SNA-125, is a dual JAK3/TrkA inhibitor being developed for the treatment of atopic dermatitis, psoriasis and pruritus. Sienna Biopharmaceuticals is headquartered in Westlake Village, California, the US.

Sienna Biopharmaceuticals Inc (SNNA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sienna Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Sienna Biopharmaceuticals Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Sienna Biopharma Raises USD40 million in Series B Financing 10
Equity Offering 12
Sienna Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 12
Sienna Biopharma Raises USD74.7 Million in IPO 13
Sienna Biopharma Raises USD0.6 Million in Private Placement of Shares 15
Sienna Biopharmaceuticals Inc – Key Competitors 16
Sienna Biopharmaceuticals Inc – Key Employees 17
Sienna Biopharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Sienna Biopharmaceuticals reports second quarter 2018 financial results 19
May 14, 2018: Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results 21
Mar 15, 2018: Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 22
Nov 09, 2017: Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results 24
Corporate Communications 25
Aug 02, 2018: Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors 25
Jul 02, 2018: Sienna Biopharmaceuticals Enters $40 Million Term Loan Agreement 26
Mar 22, 2018: Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer 27
Mar 21, 2018: Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer 28
Dec 12, 2017: Sienna Biopharmaceuticals Establishes Corporate Advisory Board 29
Jun 14, 2017: Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors 30
Mar 24, 2017: Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer 31
Feb 28, 2017: Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals 32
Legal and Regulatory 33
May 07, 2018: Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Sienna Biopharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sienna Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Sienna Biopharma Raises USD40 million in Series B Financing 10
Sienna Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 12
Sienna Biopharma Raises USD74.7 Million in IPO 13
Sienna Biopharma Raises USD0.6 Million in Private Placement of Shares 15
Sienna Biopharmaceuticals Inc, Key Competitors 16
Sienna Biopharmaceuticals Inc, Key Employees 17
Sienna Biopharmaceuticals Inc, Subsidiaries 18

List of Figures
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Sienna Biopharmaceuticals Inc (SNNA):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Invuity Inc (IVTY):企業の財務・戦略的SWOT分析
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • PG&E Corp (PCG):企業の財務・戦略的SWOT分析
    PG&E Corp (PCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • NEC Corp (6701):企業の財務・戦略的SWOT分析
    NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Teachers Mutual Bank Ltd:企業の戦略的SWOT分析
    Teachers Mutual Bank Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Canadian Tire Corp Ltd (CTC.A):企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Tenneco Inc. (TEN):企業の財務・戦略的SWOT分析
    Tenneco Inc. (TEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Carestream Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Carestream Health Inc (Carestream) a subsidiary of Onex Corp, provides dental and medical imaging systems and healthcare IT solutions. It also offers X-ray film and digital X-ray systems for non-destructive testing; and advanced materials for the precision films and electronics markets. Care …
  • Wellington Management Company LLP:企業の戦略・SWOT・財務情報
    Wellington Management Company LLP - Strategy, SWOT and Corporate Finance Report Summary Wellington Management Company LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s …
  • OPKO Health Inc (OPK):製薬・医療:M&Aディール及び事業提携情報
    Summary OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vac …
  • CDI Corp.:企業の戦略的SWOT分析
    CDI Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platf …
  • Consejo Superior de Investigaciones Cientificas-製薬・医療分野:企業M&A・提携分析
    Summary Consejo Superior de Investigaciones Cientificas (CSIC) is a research institute that provides research capacity, and human and material resources to conduct research projects. The institute offers multidisciplinary scientific and technical research, scientific and technical advice, management …
  • Spindletop Oil & Gas Co (SPND):企業の財務・戦略的SWOT分析
    Summary Spindletop Oil & Gas Co (Spindletop Oil & Gas) is an oil and gas exploration and production company. The company explores, develops and produces crude oil and natural gas in North America. It owns and maintains natural gas pipeline in Texas. Spindletop Oil & Gas also operates various gas pip …
  • Essilor International S.A.:企業の戦略・SWOT・財務分析
    Essilor International S.A. - Strategy, SWOT and Corporate Finance Report Summary Essilor International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tokyo Electron Device Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Pembina Pipeline Corp (PPL):企業の財務・戦略的SWOT分析
    Pembina Pipeline Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Paramedical Srl:企業の製品パイプライン分析2018
    Summary Paramedical Srl (Paramedical) is a medical equipment company that manufactures clinical chemistry, turbidimetry and instruments for laboratories. The company’s products include in vitro diagnostics and equipment, automated immunoassay, brochure regents and instruments, centrifuges, chemistry …
  • Achelios Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Achelios Therapeutics Inc (Achelios) is a pharmaceutical company that develops therapeutics for the treatment of pain and inflammation by topically delivered medications. The company’s lead products include Topofen, a product for the indication of acute migraine, prophylactic migraine, osteo …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆